SCHEMBL2210020

SCHEMBL2210020

FC(F)(F)Oc1ccc2nccc(Oc3ccc(Nc4nnc(-c5ccc(Cl)cc5)c5ccccc45)cc3)c2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 9/20 0.48
ENPP3 O14638 2/20 0.46
MAPT P10636 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
TP53 P04637 1/20 0.43
FGFR2 P21802 2/20 0.43
LMNA P02545 1/20 0.43
AURKA O14965 2/20 0.42
AURKB Q96GD4 2/20 0.42
TPX2 Q9ULW0 2/20 0.42
GAA P10253 1/20 0.41
KDM4E B2RXH2 1/20 0.41
PDE5A O76074 1/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
HPGD P15428 1/20 0.41
ALOX15 P16050 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15663409 0.93 KDR (0.48) KDRENPP3MAPTSMN1; SMN2TP53
SCHEMBL2209315 0.89 MAPT (0.54) KDRENPP3MAPTTP53FGFR2
SCHEMBL2210553 0.86 FGFR2 (0.48) KDRENPP3MAPTSMN1; SMN2TP53
SCHEMBL2210774 0.83 AURKA (0.49) KDRENPP3MAPTSMN1; SMN2FGFR2
SCHEMBL3703048 0.83 KDR (0.50) KDRENPP3MAPTTP53LMNA
SCHEMBL2210539 0.82 AURKA (0.54) KDRFGFR2AURKAAURKBTPX2
SCHEMBL15663382 0.81 MAPT (0.54) KDRENPP3MAPTTP53FGFR2
SCHEMBL2211767 0.81 FGFR2 (0.58) KDRENPP3MAPTTP53FGFR2
SCHEMBL2966793 0.80 KDR (0.51) KDRENPP3MAPTSMN1; SMN2TP53
SCHEMBL2209159 0.79 KDR (0.50) KDRENPP3MAPTLMNAAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7981891-B2 Aurora kinase modulators and method of use AMGEN INC. (US) 2011-07-19 US claimed
US-20100280008-A1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC. (US) 2010-11-04 US claimed
EP-2137177-B1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC (US) 2014-05-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280008-A1 AURORA KINASE MODULATORS AND METHOD OF USE AURKC, AURKA, CDK1 KDR 644/4885ENPP3 1630/4885MAPT 1693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.